Milestone Pharmaceuticals MIST Q1 2026 Earnings Significant EPS Miss as PreRevenue Biotech Continues Pipeline Development Concentrix CNXC Q1 2026 Earnings EPS Miss and Revenue NonDisclosure Weigh on Sentiment ASND Q1 2026 Earnings Wide EPS Miss as Ascendis Pharma Remains PreRevenue Stock Edges Higher BW Q1 2026 Earnings Significant EPS Miss Leads to Stock Decline NEWTI Q1 2026 Earnings EPS Misses Estimates Revenue Not Disclosed OTEX Q1 2026 Earnings EPS Surpasses Estimates as Cloud and AI Initiatives Gain Traction